News

The director of the Comprehensive Epilepsy Center at NYU Langone provided insight on whether a newly discovered biomarker can play a role in the creation of modalities to detect SUDEP risk. [WATCH TIME: 3 minutes]

Mind Moments™, a podcast from NeurologyLive®, brings you an exclusive interview with Karl Doghramji, MD, FAASM, DFAPA.

Chaired by Jennifer Graves, MD, PhD, MAS, the presentations also feature UC San Diego Health experts Jenelle Raynowska, MD; Jennifer Yang, MD; and Anastasie Dunn-Pirio, MD. [WATCH TIME: 1 hour, 23 minutes]

Ilya Kister, MD, professor of neurology, NYU Grossman School of Medicine, discussed his surprising results from ECTRIMS, which found no evidence of wearing off with ocrelizumab (Ocrevus; Genentech).

Contrary to previous expectations, 30 minutes of social media before bedtime did not significantly increase arousal or disturb sleep for study participants.

The guideline updates previous recommendations for dopaminergic medications published in 2002, integrating new medications and formulations.

Patients with REM sleep percentage less than 15% were associated with poorer horizontal optokinetic nystagmus grades and more severe illness.

The postdoctoral scholar at the University of Iowa commented on why the multiple sclerosis field should lean on registered dietitians to help alleviate symptoms of patients with multiple sclerosis. [WATCH TIME: 2 minutes]

The findings, which suggest that high plasma GFAP levels are parallel with AD and are markers of tau pathology, hold important implications in facilitating the detection of Alzheimer disease, particularly in the preclinical stage.

Ali Rezai, MD, executive chair of the Rockefeller Neuroscience Institute at West Virginia University, provided an overview of FUS technology and its use in opening the blood-brain barrier.

A higher incidence of gastrointestinal events was observed in the treatment group compared with placebo, similar to what was seen in clinical trials of AMX0035 in amyotrophic lateral sclerosis.

Discussing cognitive behavioral therapy for patients with MS, the associate professor of Physical Medicine and Rehabilitation and research nonclinical psychologist at the University of Michigan Medicine mentioned different therapeutic options that can benefit this patient population. [WATCH TIME: 3 minutes]

In addition to changes in CCL2 levels, anxiety and health-related quality of life were both significantly increased in both the valproate and add-on levetiracetam groups.

The postdoctoral scholar at the University of Iowa discussed the importance of understanding more about the effects of diet and how it is managed when caring for a patient with multiple sclerosis. [WATCH TIME 3 minutes]

The director of the Comprehensive Epilepsy Center at NYU Langone discussed his recently published research, which identified a novel biomarker for sudden unexpected death in epilepsy.

Anna Kratz, PhD, associate professor of Physical Medicine & Rehabilitation, University of Michigan Medicine, spoke to the benefits of a multifaceted approach to managing fatigue for patients with multiple sclerosis.

Results outline secondary end points, which follow previously reported data on the AMBAR study’s primary end points, including delay in cognitive and functional decline in patients with AD.

The associate professor of Physical Medicine & Rehabilitation and research nonclinical psychologist at the University of Michigan Medicine discussed challenges when addressing fatigue, as well as the need to integrate digital tools for patients with MS. [WATCH TIME: 4 minutes]

The long-term benefits observed were due to maintenance of the early effect, rather than any additional benefit accrued after 90 days of the initial event, with no evidence either of rebound or loss of benefit.

Robert Zivadinov, MD, PhD, provided insight on the different components that need to be addressed to help stop—and potentially reverse—neurodegeneration in MS.

Over 26 weeks of treatment, masupirdine demonstrated a sustained and durable effect on outcomes such as cognition and dementia-related psychosis.

Beginning enrollment in 2022, the NAUTILUS pivotal study will be the first in the United States to evaluate brain-responsive neuromodulation in patients with idiopathic generalized epilepsy.

The assistant professor of neurology at Weill Cornell Medicine provided thoughts on the need to identify high-risk individuals and put efforts towards improving recurrent stroke rates. [WATCH TIME: 2 minutes]

Ivana Rubino, PhD, the head of Medical for Global Alzheimer at Biogen, offered her perspective on the recently presented data at CTAD 2021.

The director of the Comprehensive Epilepsy Center at NYU Langone discussed the critical findings on how heart rate variability may stratify individual SUDEP risk. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive.

Despite being discontinued early, patients in the high-dose group of the PLEO-CMT trial experienced statistically significant improvement in Overall Neuropathy Limitations Scale total score.

A stronger association between the 2 conditions was seen in younger patients and men with epilepsy than their counterparts in the matched cohort of more than 9000 individuals.

The associate professor of Physical Medicine & Rehabilitation and nonclinical research psychologist at University of Michigan Medicine discussed the complexities of fatigue as a symptom following her presentation at CMCS 2021.

A presentation at CTAD 2021 included data from 5 patients enrolled in a phase 2a trial to evaluate neurocognitive, imaging, and safety outcomes of the therapeutic approach in early AD dementia.